MIG Capital fuels €514M growth in 2025 with deep-tech and life sciences bets
2025: MIG Funds Invest €32 Million in Portfolio Companies
MIG Capital AG has reflected on another challenging business year. In 2025, its portfolio companies received nearly €32 million (2024: €41 million) across 24 funding rounds from the MIG funds. Together with co-investors and additional backers, these firms secured over €514 million in total (2024: €232 million). By the end of 2025, the MIG funds had reached a milestone of approximately €800 million invested in promising deep-tech and life sciences startups since their inception over two decades ago.
At the close of 2025, MIG Capital's portfolio included more than 30 young companies. New investments in 2025 included CoreMedic (Series B extension), ASTRA Therapeutics (seed funding), and NcodiN (seed funding). Several portfolio companies achieved major milestones: IQM (a €320 million funding round), Look Up (a €50 million funding round), AMSilk (two critical steps toward becoming a mid-sized enterprise), and AC Immune (positive interim results from a Phase II trial of its active immunotherapy, ACI-7104.056).
Michael Motschmann, Managing Partner at MIG Capital, stated: "We are making a significant contribution to enabling highly innovative business models in Germany and Europe to turn their ideas into forward-looking progress." Reflecting on 2025, he added: "This was another difficult year for growth financing. That's why it was all the more important to provide our portfolio companies with targeted capital alongside strong co-investors, giving them planning security. The fact that many of our investments have reached key technological and operational milestones confirms our selective, long-term approach."
Since last year, Dr. Nicolas Rose-André has strengthened MIG Capital's deep-tech division, further expanding and diversifying the venture capital firm's investment team. Currently, eleven experts work for MIG Capital, leveraging international experience, entrepreneurial expertise, and broad sector knowledge to identify and support promising companies in life sciences and deep tech.
In 2025, the MIG funds distributed €8.5 million to investors, benefiting shareholders in MIG Funds 2, 4, 6, 8, and 16. These payouts resulted from the divestments of biocrates and Advanced Medical Balloons. Wealthpilot was also sold, with distributions to MIG Fund 16 investors made in January 2026.
Looking ahead to 2026, Dr. Matthias Kromayer, Managing Partner at MIG Capital, commented: "We continue to see major opportunities for technologically strong companies. Europe and Germany boast excellent technologies and highly skilled founding teams. The challenge lies less in innovation itself than in execution, scaling, and international visibility. This is where our experience and network come into play. The next breakthroughs will come from clear focus and perseverance—and that's what we'll prioritize in 2026."
Read also:
- Federal Funding Supports Increase in Family Medicine Residency Program, Focusing on Rural Health Developments
- Potential Role of DHA in Shielding the Brain from Saturated Fats?
- Alternative Gentle Retinoid: Exploring Bakuchiol Salicylate for Sensitive Skin
- Hanoi initiates a trial program for rabies control, along with efforts to facilitate the transition from the dog and cat meat trade industry.
